- Aurinia Pharmaceuticals (NASDAQ:AUPH) completed targeted enrollment of 324 patients for the AURORA Phase 3 trial ahead of schedule due to high patient demand with 358 lupus nephritis patients randomized in sites across 27 countries.
- The AURORA clinical trial is a global, double-blind, placebo-controlled study to evaluate whether voclosporin when added to background therapy of mycophenolate mofetil/CellCept® can increase speed of and overall renal response rates in the presence of low dose steroids.
- The primary endpoint for the study is complete renal response at 52 weeks, after which patients can choose to enroll into a 104-week blinded extension study.
- “We look forward to sharing the results of the trial in late Q4 2019 and to completing our NDA submission in Q2 2020,” said Neil Solomons, M.D., Aurinia’s Chief Medical Officer.
- Shares +3%
- Press Release